Pelotonia

What it reported doing in 2024

Pelotonia supports high-risk, high-reward cancer research initiatives at the Ohio state university comprehensive cancer center arthur g. James cancer hospital and solove research institute. The funds raised support projects that address many areas of cancer research, including prevention, diagnosis, treatment, psychosocial issues, accelerated drug development, and large initiatives that help change the landscape of cancer care and offer help and hope to patients and families from around the world. Pelotonia funds are not restricted to specific cancer types, allowing us to invest in innovation across all cancers, funding the highest priority and quality research annually. See schedule o.in fy 2023, pelotonia awarded fellowship program awards to empower young innovators across academic fields and disciplines to pursue a career in cancer research; idea grants to enable scientists to pursue new approaches to cancer research; and statewide initiative grants focused on assessing survival and quality of life for advanced stage lung cancer, smoking cessation, and reducing the high breast cancer mortality among african american women in Ohio. Pelotonia continued ongoing programmatic investments in the pelotonia institute for immuno-oncology (piio); a comprehensive bench-to-bedside research initiative focused on harnessing the immune system to fight cancer; recruitment and retention of top cancer scientists; sophisticated equipment required for cutting-edge cancer discoveries; strategic research investments in the drug development institute; digital pathology; and total cancer care protocol programs at the osuccc - james.

Financial Efficiency

• Mission deployment rate: 72.3%; rating input score 72
• Program expense ratio: 89.2%; rating input score 89
• Fundraising efficiency: $41.69 raised per $1 spent on fundraising; rating input score 73; 73rd percentile among comparable filings

Transparency & Controls

• Consistency checks: 94.1%; rating input score 94; 20th percentile among comparable filings
• Pay-setting controls: 5 of 6 controls in place; rating input score 83
  • Compensation committee: Pass
  • Independent consultant: Missing
  • Other Form 990s reviewed: Pass
  • Written employment contract: Pass
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: 89.9%; rating input score 90; 20th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 91.7%; rating input score 92; 24th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 19.8%; rating input score 82; 82nd percentile among comparable filings
• Total-asset coverage ratio: 0.88; rating input score 31; 31st percentile among comparable filings
• Liabilities to assets ratio: 0.12; rating input score 70; 70th percentile among comparable filings
• Officer compensation ratio: 5.3%; rating input score 48; 48th percentile among comparable filings

Growth

• Program expense growth: 15.8% per year; rating input score 100; 85th percentile among comparable filings
• Revenue growth: 26% per year; rating input score 100; 95th percentile among comparable filings
• Asset growth: 7.9% per year; rating input score 100; 54th percentile among comparable filings